TSHA

Taysha Gene Therapies Stock Price

25.76
0.72 (2.88%)
Upgrade to Real-Time
Afterhours (Closed)
25.76

Low
18.16

52 Week Range

High
33.84

Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
Taysha Gene Therapies Inc TSHA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.72 2.88% 25.76 20:00:00
Open Price Low Price High Price Close Price Prev Close
24.49 24.485 25.98 25.76 25.04
Bid Price Ask Price Spread News
20.30 31.00 10.70 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,629 162,744 $ 24.92 $ 4,055,109 174,017 18.16 - 33.84
Last Trade Time Type Quantity Stock Price Currency
17:07:10 1 $ 25.76 USD

Taysha Gene Therapies Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 976.75M 37.92M 16.49M $ - $ - -2.71 -7.80
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 13.17k 26.90%

more financials information »

Taysha Gene Therapies News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical TSHA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week24.5426.9923.4825.20247,6591.224.97%
1 Month21.9926.9921.4023.58218,3133.7717.14%
3 Months22.1527.0018.6822.98141,1013.6116.3%
6 Months21.5533.8418.6824.30120,8984.2119.54%
1 Year22.2533.8418.1623.31136,8603.5115.78%
3 Years22.2533.8418.1623.31136,8603.5115.78%
5 Years22.2533.8418.1623.31136,8603.5115.78%

Taysha Gene Therapies Description

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.


Your Recent History
NASDAQ
TSHA
Taysha Gen..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.